# Hoffmann-La Roche: Phase 2 study completed, 51 enrolled (Facioscapulohumeral Muscular Dystrophy (FSHD))

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy |
| NCT ID | NCT05548556 |
| Phase | Phase 2 |
| Status | completed |
| Conditions | Facioscapulohumeral Muscular Dystrophy (FSHD) |
| Intervention types | drug |
| Target enrollment | 51 |
| Site countries | United States, Denmark, Italy, United Kingdom |
| Posted | 2022-09-21 |
| Planned start | 2023-02-07 |
| Event | Completed |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05548556). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.